Internal Reference Number: FOI_6649
Date Request Received: 22/06/2022 00:00:00
Date Request Replied To: 14/07/2022 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: Please note, any numbers less than or equal to 5 have been suppressed in order to protect patient confidentiality, as per Information Governance regulations. • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Abemaciclib + Fulvestrant <5 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab +Nab-paclitaxel/Paclitaxel 0 • Capecitabine as a single agent 9 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent 0 • Lapatinib 0 • Neratinib <5 • Parp Inhibitors (Olaparib/Talazoparib) <5 • Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 34 • Palbociclib + Fulvestrant <5 • Pembrolizumab 0 • Platinum (e.g. carboplatin or cisplatin) as a single agent 0 • Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan 0 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent <5 • Taxane and/or Anthracycline in combination 34 • Trastuzumab as a single agent or in combination 39 • Trastuzumab emtansine 6 • Transtuzumab deruxtecan <5 • Any other active systemic anti-cancer therapy <5 | |
| Question Number 2: In the past 3 months, how many early/locally advanced breast cancer (Stages 1 to 3B) patients were treated with: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) • Taxane and/or Anthracycline (monotherapy or in combination) • Any other active systemic anti-cancer therapy | |
| Answer To Question 2: • Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) 0 • Taxane and/or Anthracycline (monotherapy or in combination) 14 • Any other active systemic anti-cancer therapy 58 | |
| To return to the list of all the FOI requests please click here |
Our staff at SA¹ú¼Ê´«Ã½ Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
